Exicure, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene regulatory and immuno-oncology therapeutics-based on its proprietary spherical nucleic acid (SNA) technology. SNAs are nanoscale constructs consisting of densely packed synthetic nucleic acid sequences that are radially arranged in three dimensions. The Companyâ€™s intellectual property portfolio includes 125 pending patent applications and 45 allowed or issued patents. These filings impact numerous jurisdictions worldwide, and they cover a range of inventions, including fundamental nanoparticle manufacturing breakthroughs and numerous application-specific improvements.